3
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: not found

      Effects of lidocaine and the inclusion complex with 2-hydroxypropyl-β-cyclodextrin on cell viability and proliferation of oral squamous cell carcinoma.

      Read this article at

      ScienceOpenPublisherPubMed
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Squamous cell carcinoma (SCC) is a malignant disease that affects the oral cavity. Lidocaine has shown antiproliferative and cytotoxic activity on several cell types. The rapid dispersion is a limitation issue; however, the complexation in cyclodextrin improved pharmacological features and modified the drug release. This study investigated the effects of lidocaine (lido) complexed with 2-hydroxypropyl-β-cyclodextrin (HP-β-CD-lido) on cell viability and proliferation of human tongue squamous cell carcinoma SCC9 and SCC25.

          Related collections

          Author and article information

          Journal
          J Pharm Pharmacol
          The Journal of pharmacy and pharmacology
          Wiley
          2042-7158
          0022-3573
          Jul 2018
          : 70
          : 7
          Affiliations
          [1 ] Department Foundation Sciences, School of Dental Medicine, East Carolina University, Greenville, NC, USA.
          [2 ] Department of Physiological Sciences, Piracicaba Dental School, University of Campinas (UNICAMP), Piracicaba, SP, Brazil.
          [3 ] Department of Immunology and Molecular Biology, São Leopoldo Mandic Research Center, Campinas, SP, Brazil.
          [4 ] Laboratory of Environmental Nanotechnology, Institute of Science and Technology of Sorocaba, São Paulo State University (UNESP), Sorocaba, SP, Brazil.
          Article
          10.1111/jphp.12917
          29633269
          2ee49bf0-9af8-496b-813c-f07178016337
          © 2018 Royal Pharmaceutical Society.
          History

          2-hydroxypropyl-β-cyclodextrin,anticancer activity,lidocaine,squamous cell carcinoma

          Comments

          Comment on this article